



June 15, 2015

AnGes MG, Inc.

**Increase in Titers of Antibodies against Ebola Glycoprotein Confirmed in  
Initial Equine Study for Ebola Polyclonal Antibody Therapy  
Using DNA Vaccine Technology**

AnGes MG, Inc. ("AnGes") announced that it has obtained positive results in an initial equine study for polyclonal antibodies as a treatment for the Ebola virus utilizing gene therapy technology.

As announced on January 14, 2015, AnGes initiated the development of therapeutic equine polyclonal antibodies for the Ebola virus using DNA vaccine technology in Japan. Antibodies from horses immunized with the DNA vaccine encoding the Ebola virus glycoprotein antigen will be isolated and purified then developed to treat the Ebola virus in humans.

AnGes started an initial study in March 2015 to examine the antibody productions of thoroughbred horses injected with the DNA vaccine. The study verified the antibody titers against Ebola glycoprotein in equine serum after injections of the DNA vaccine. The results showed a significant increase in the antibody titers against Ebola glycoprotein.

"I believe this is a significant step toward early realization of equine polyclonal antibodies as a treatment for the Ebola virus," said Ei Yamada, Ph.D., President and CEO of AnGes. "Ebola infection cases have been reported almost every year before the Ebola outbreak in West Africa last year and will continue to be a threat in which emergency measures must be taken here in Japan as well. The therapeutic equine polyclonal antibodies may be used for emergency measures in Japan such as treatment for patients afflicted with the Ebola virus and reserves for medical workers who are exposed to a high risk of infection"

Following the results of the initial study, AnGes will prepare a development plan aimed at an early realization of therapeutic equine polyclonal antibodies for the Ebola virus.

## Equine Polyclonal Antibody Therapy for Ebola Virus Using DNA Vaccine Technology

The therapeutic equine polyclonal antibodies developed by AnGes utilizes DNA vaccine encoding the Ebola virus glycoprotein antigen. Antibodies from horses immunized with the DNA vaccine will be isolated and purified, then developed to treat the Ebola virus in humans. DNA vaccine technology enables AnGes to produce the polyclonal antibodies quickly and safely, as there will be no need to handle the highly pathogenic virus. AnGes believes the therapeutic equine polyclonal antibodies will be a suitable treatment for the Ebola virus, which requires emergency measures.

AnGes has signed an agreement with Vical Incorporated (San Diego, CA, President & CEO: Vijay B. Samant) regarding Vical's DNA vaccine technology, for the rights to exclusively develop and commercialize the equine polyclonal antibody therapy in Japan.

###

*Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.*

<p>AnGesMG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 <a href="http://www.anges-mg.com">http://www.anges-mg.com</a></p>
--